Across TCGA pan-cancer cohorts, TIGAR Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TIGAR data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TIGAR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TIGAR expression acts as an unfavorable survival marker.
SKCM, UCEC, and PRAD are the cancer types where TIGAR Mutation most reproducibly stratifies survival.